SpringerLink
Log in

Viral Markers and Their Relevance in Liver Disease and Transplantation

  • Chapter
  • First Online:
Peri-operative Anesthetic Management in Liver Transplantation

  • 679 Accesses

Abstract

Hepatitis is an inflammation of the liver, mainly caused by a viral infection. There are five principal hepatitis viruses, namely types A, B, C, D, and E. These viruses are quite divergent in their structure, epidemiology, route of transmission, incubation period, clinical presentations, natural history, diagnosis, and preventive and treatment options (Table 6.1). HAV and HEV are important because of the burden of illness they cause and the potential for outbreaks and epidemic spread. Hepatitis B and C are especially prevalent and lead to chronic hepatitis—the most important cause of liver cirrhosis and cancer [1]. Currently 240 million people are chronically infected with hepatitis B and 184 million people have antibodies against hepatitis C [1, 2].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (Brazil)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (Brazil)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (Brazil)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (Brazil)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Alter MJ. Epidemiology of hepatitis B in Europe and worldwide. J Hepatol. 2003;39:S64–9.

    Article  Google Scholar 

  2. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705–14.

    Article  Google Scholar 

  3. Garcia-Retortillo M, Forns X, Feliu A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology. 2002;35:680–7.

    Article  Google Scholar 

  4. Siegl G. Virology of hepatitis. In: Zuckerman AJ, editor. Viral hepatitis and liver disease. New York: Alan R Liss; 1988. p. 3–7.

    Google Scholar 

  5. Dienstag JL, Szmuness W, Stevens CE, Purcell RH. Hepatitis A virus infection: new insights from seroepidemiologic studies. J Infect Dis. 1978;137:328–40.

    Article  CAS  Google Scholar 

  6. Wright R, Millward-Salder GH, Bull FG. Acute viral hepatitis. In: Wright R, Millward-Sadler GH, Alberti KGMM, Karran S, editors. Liver and biliary disease. London: Bailliere Tindall; 1985. p. 677–767.

    Google Scholar 

  7. Lemon SM. Type A viral hepatitis. New developments in an old disease. N Engl J Med. 1985;313:1059–67.

    Article  CAS  Google Scholar 

  8. Gust ID, Feinstone SM. Clinical features. In: Hepatitis A. Florida: CRC Press; 1988. p. 145–62.

    Google Scholar 

  9. Coulepis AG, Locarnini SA, Lehmann NI, Gust ID. Detection of hepatitis A virus in the feces of patients with naturally acquired infections. J Infect Dis. 1980;141:151–6.

    Article  CAS  Google Scholar 

  10. Yotsuyanagi H, Koike K, Yasuda K, et al. Prolonged fecal excretion of hepatitis A virus in adult patients with hepatitis A as determined by polymerase chain reaction. Hepatology. 1996;24:10–3.

    Article  CAS  Google Scholar 

  11. Reed C, Gustafson T, Siegel J, Duer P. Nosocomial transmission of hepatitis A from a hospital acquired case. Pediatr Infect Dis. 1984;3:300–3.

    Article  CAS  Google Scholar 

  12. Krober MS, Bass JW, Brown JD, Lemon SM, Rupert KJ. Hospital outbreak of hepatitis A: risk factors for spread. Pediatr Infect Dis. 1984;3:296–9.

    Article  CAS  Google Scholar 

  13. Drusin LM, Sohmer M, Groshen SL, Spiritos MD, Senterfit LB, Christenson WN. Nosocomial hepatitis A infection in a pediatric intensive care unit. Arch Dis Child. 1987;62:690–5.

    Article  CAS  Google Scholar 

  14. Burkholder BT, Coronado VG, Brown J, et al. Nosocomial transmission of hepatitis A in a pediatric hospital traced to an anti-hepatitis A virus negative patient with immunodeficiency. Pediatr Infect Dis J. 1995;14:261–6.

    Article  CAS  Google Scholar 

  15. Bradley DW, Maynard JE, Hindman SH, et al. Serodiagnosis of viral hepatitis A: detection of acute-phase immunoglobulin M anti-hepatitis A virus by radioimmunoassay. J Clin Microbiol. 1977;5:521–30.

    Article  CAS  Google Scholar 

  16. Krawczynski K. Hepatitis E. Hepatology. 1993;17:932–41.

    Article  CAS  Google Scholar 

  17. Goldsmith R, Yarbough PO, Reyes GR, et al. Enzyme-linked immunosorbent assay for diagnosis of acute sporadic hepatitis E in Egyptian children. Lancet. 1992;339:328–31.

    Article  CAS  Google Scholar 

  18. Balayan MS, Andjaparidze AG, Savinskaya SS, et al. Evidence for a virus in non-A, non-B hepatitis transmitted via the fecal-oral rout. Intervirology. 1983;20:23–31.

    Article  CAS  Google Scholar 

  19. Bradley DW, Krawczynski K, Kane MA. Hepatitis E. In: Belshe RB, editor. Textbook of human virology. 2nd ed. St Louis; 1991. p. 781–90.

    Google Scholar 

  20. Khuroo MS, Duermeyer W, Zargar SA, et al. Acute sporadic non-A, non-B hepatitis in India. Am J Epidemiol. 1983;118:360–4.

    Article  CAS  Google Scholar 

  21. Kane MA, Bradley DW, Shretha SM, et al. Epidemic non-A, non-B hepatitis in Nepal. JAMA. 1984;252:3140–5.

    Article  CAS  Google Scholar 

  22. Lu L, Li C, Hagedorn CH. Phylogenetic analysis of global hepatitis E virus sequences: genetic diversity, subtypes and zoonosis. Rev Med Virol. 2006;16:5–36.

    Article  CAS  Google Scholar 

  23. Aggarwal R, Jameel S. Hepatitis E. Hepatology. 2011;54:2218–26.

    Article  Google Scholar 

  24. Aggarwal R, Naik S. Epidemiology of hepatitis E: current status. J Gastroenterol Hepatol. 2009;24:1484–93.

    Article  Google Scholar 

  25. Naik S, Aggarwal R, Salunke P, et al. A large waterborne viral hepatitis E epidemic in Kanpur, India. Bull WHO. 1992;70:597–604.

    CAS  Google Scholar 

  26. Zhuang H. Hepatitis E and strategies for its control. Basel: Karger; 1992.

    Google Scholar 

  27. Khuroo M, Teli M, Skidmore S, et al. Incidence and severity of viral hepatitis in pregnancy. Am J Med. 1981;70:252–5.

    Article  CAS  Google Scholar 

  28. Kamar N, Garrouste C, Haagsma EB, et al. Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology. 2011;140:1481–9.

    Article  Google Scholar 

  29. Aggarwal R. Diagnosis of hepatitis E. Nat Rev Gastroenterol Hepatol. 2013;10:24–33.

    Article  CAS  Google Scholar 

  30. Tiollais P, Charnay P, Vyas GN. Biology of hepatitis B virus. Science. 1981;213:406–11.

    Article  CAS  Google Scholar 

  31. McMahon BJ, Alward WLM, Hall DB, et al. Acute hepatitis B virus infection. Relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis. 1985;151:599–603.

    Article  CAS  Google Scholar 

  32. Hall AJ, Winter PD, Wright R. Mortality of hepatitis B positive blood donors in England and Wales. Lancet. 1985;1:91–3.

    Article  CAS  Google Scholar 

  33. Weissberg JI, Andres LL, Smith CI, et al. Survival in chronic hepatitis B: an analysis of 379 patients. Ann Intern Med. 1984;101:613–6.

    Article  CAS  Google Scholar 

  34. Beasley RP, Hwang LY. Epidemiology of hepatocellular carcinoma. In: Vyas GN, Dienstag JL, Hoofnagle JH, editors. Viral hepatitis and liver disease. Orlando: Grune & Statton; 1984. p. 209.

    Google Scholar 

  35. Francis DP, Favero MS, Maynard JE. Transmission of hepatitis B virus. Semin Liver Dis. 1981;1:27–32.

    Article  CAS  Google Scholar 

  36. Seeff LB, Wright EC, Zimmerman HJ, et al. Type B hepatitis after needle-stick exposures: prevention with hepatitis B immunoglobulin. Final report of the Veterans Administration Cooperative Study. Ann Intern Med. 1978;88:285.

    Article  CAS  Google Scholar 

  37. Scott RM, Snitbhan D, Bancroft WH, et al. Experimental transmission of hepatitis B virus by semen and saliva. J Infect Dis. 1980;142:67–71.

    Article  CAS  Google Scholar 

  38. Shikata T, Karasawa T, Abe K, et al. Hepatitis B antigen and infectivity of hepatitis B virus. J Infect Dis. 1977;136:571–6.

    Article  CAS  Google Scholar 

  39. Denes AE, Smith JL, Maynard JE, et al. Hepatitis B infection in physicians: results of a nation-wide seroepidemiology survey. JAMA. 1978;239:210–2.

    Article  CAS  Google Scholar 

  40. Olubuyide IO, Ola SO, Aliyu B, et al. Hepatitis B and C in doctors and dentists in Nigeria. Q J Med. 1997;90:417–22.

    Article  CAS  Google Scholar 

  41. Kim WR, Terrault NA, Pedersen RA, et al. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology. 2009;137(5):1680–6.

    Article  Google Scholar 

  42. European liver transplant registry. Available at http://www.eltr.org.

  43. O’Grady JG, Smith HM, Davies SE, et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol. 1992;14(1):104–11.

    Article  Google Scholar 

  44. Todo S, Demetris AJ, Van Thiel D, et al. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology. 1991;13(4):619–26.

    CAS  Google Scholar 

  45. Steinmuller T, Seehofer D, Rayes N, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology. 2002;35(6):1528–35.

    Article  Google Scholar 

  46. Kim WR, Poterucha JJ, Kremers WK, et al. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl. 2004;10(8):968–74.

    Article  Google Scholar 

  47. **e SB, Zhu JY, Ying Z, et al. Prevention and risk factors of the HBV recurrence after orthotopic liver transplantation: 160 cases follow-up study. Transplantation. 2010;90(7):786–90.

    Article  Google Scholar 

  48. Chun J, Kim W, Kim BG, et al. High viremia, prolonged lamivudine therapy and recurrent hepatocellular carcinoma predict posttransplant hepatitis B recurrence. Am J Transplant. 2010;10(7):1649–59.

    Article  CAS  Google Scholar 

  49. Faria LC, Gigou M, Roque-Afonso AM, et al. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology. 2008;134(7):1890–9. quiz 2155

    Article  Google Scholar 

  50. Yi NJ, Suh KS, Cho JY, et al. Recurrence of hepatitis B is associated with cumulative corticosteroid dose and chemotherapy against hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl. 2007;13(3):451–8.

    Article  Google Scholar 

  51. Saab S, Yeganeh M, Nguyen K, et al. Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation. Liver Transpl. 2009;15(11):1525–34.

    Article  Google Scholar 

  52. Cholongitas E, Goulis J, Akriviadis E, Papatheodoridis GV. Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis B virus recurrence after liver transplantation: a systematic review. Liver Transpl. 2011;17:1176–90.

    Article  Google Scholar 

  53. Rao W, Wu X, **u D. Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta-analysis. Transpl Int. 2009;22:387–94.

    Article  CAS  Google Scholar 

  54. Cholongitas E, Papatheodoridis GV. High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review. Am J Transplant. 2013;13:353–62.

    Article  CAS  Google Scholar 

  55. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl. 2000;6:429–33.

    Article  CAS  Google Scholar 

  56. Degertekin B, Han SH, Keeffe EB, et al. Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after livertransplantation. Am J Transplant. 2010;10(8):1823–33.

    Article  CAS  Google Scholar 

  57. Wong SN, Chu CJ, Wai CT, Howell T, Moore C, Fontana RJ, Lok AS. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulinin patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl. 2007 Mar;13(3):374–81.

    Article  Google Scholar 

  58. Singer GA, Zielsdorf S, Fleetwood VA, et al. Limited hepatitis B immunoglobulin with potent nucleos(t)ide analogue is a cost-effective prophylaxis against hepatitis B virus after liver transplantation. Transplant Proc. 2015 Mar;47(2):478–84.

    Article  CAS  Google Scholar 

  59. Cholongitas E, Vasiliadis T, Antoniadis N, Goulis I, Papanikolaou V, Akriviadis E. Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues afterhepatitis B immunoglobulin discontinuation. Transpl Infect Dis. 2012 Oct;14(5):479–87.

    Article  CAS  Google Scholar 

  60. Buti M, Mas A, Prieto M, Casafont F, Gonzalez A, Miras M, et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol. 2003;38:811–7.

    Article  CAS  Google Scholar 

  61. Fung J, Cheung C, Chan SC, Yuen MF, Chok KS, Sharr W, et al. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology. 2011;141:1212–9.

    Article  CAS  Google Scholar 

  62. Wadhawan M, Gupta S, Goyal N, Taneja S, Kumar. Living related liver transplantation for hepatitis b–related liver disease without hepatitis b immune globulin prophylaxis. Liver Transpl. 2013;19:1030–5.

    Article  Google Scholar 

  63. Gane EJ, Patterson S, Strasser SI, McCaughan GW, Angus PW. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates. Liver Transpl. 2013;19(3):268–74.

    Article  Google Scholar 

  64. Rizzetto M. Hepatitis D: thirty years after. J Hepatol. 2009;50(5):1043–50.

    Article  CAS  Google Scholar 

  65. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet. 2011;378(9785):73–85.

    Article  Google Scholar 

  66. Fattovich G, Giustina G, Christensen E, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on ViralHepatitis (Eurohep). Gut. 2000;46(3):420–6.

    Article  CAS  Google Scholar 

  67. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med. 1993;329(25):1842–7.

    Article  CAS  Google Scholar 

  68. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 1995;332:1463–6.

    Article  CAS  Google Scholar 

  69. Minuk G, Assy N. The consequences of hepatitis C viral infection in humans. Can J Gastroenterol. 1995;9:373–6.

    Google Scholar 

  70. Thein HH, Yi Q, Dore GJ, et al. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008;48:418–31.

    Article  Google Scholar 

  71. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol. 2000;32:673–84.

    Article  CAS  Google Scholar 

  72. Berenguer M, Aguilera V, Prieto M, et al. Delayed onset of severe hepatitis C-related liver damage following liver transplantation: a matter of concern? Liver Transpl. 2003;9(11):1152–8.

    Article  Google Scholar 

  73. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009;373:582–92.

    Article  CAS  Google Scholar 

  74. Cholongitas E, Papatheodoridis GV, Burroughs AK. Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol. 2010;52:272–9.

    Article  CAS  Google Scholar 

  75. Huprikar S, Danziger-Isakov L, Ahn J, et al. Solid organ transplantation from hepatitis B virus-positive donors: consensus guidelines for recipient management. Am J Transplant. 2015;15:1162–72.

    Article  CAS  Google Scholar 

  76. Lucey MR, Terrault N, Ojo L, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl. 2013;19:3–26.

    Article  Google Scholar 

  77. Skagen CL, Jou JH, Said A. Risk of de novo hepatitis in liver recipients from hepatitis-B core antibody-positive grafts—a systematic analysis. Clin Transpl. 2011;25:E243–9.

    Article  Google Scholar 

  78. Chang MS, Olsen SK, Pichardo EM, et al. Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: a 12-year experience. Transplantation. 2013;95:960–5.

    Article  CAS  Google Scholar 

  79. MacConmara MP, Vachharajani N, Wellen JR, et al. Utilization of hepatitis B core antibody-positive donor liver grafts. HPB (Oxford). 2012;14:42–8.

    Article  Google Scholar 

  80. Saab S, Waterman B, Chi AC, et al. Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: a systematic review. Liver Transpl. 2010;16:300–7.

    Article  Google Scholar 

  81. Yen RD, Bonatti H, Mendez J, et al. Case report of lamivudine-resistant hepatitis B virus infection post liver transplantation from a hepatitis B core antibody donor. Am J Transplant. 2006;6:1077–83.

    Article  CAS  Google Scholar 

  82. Hwang JP, Lok AS. Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol. 2014;11:209–19.

    Article  CAS  Google Scholar 

  83. FDA Hepatitis Update - Hepatitis B reactivation with certain immunesuppressing and anti-cancer drugs. Infectious Diseases Society of America (IDSA). Updated 29 Oct 2013. Accessed 22 Mar 2018.

    Google Scholar 

  84. Saidi RF, Jabbour N, Shah SA, et al. Liver transplantation from hepatitis B surface antigen-positive donors. Transplant Proc. 2013;45:279–80.

    Article  CAS  Google Scholar 

  85. Levitsky J, Formica RN, Bloom RD, et al. The American Society of transplantation consensus conference on the use of hepatitis C viremic donors in solid organ transplantation. Am J Transplant. 2017;17:2790–802.

    Article  CAS  Google Scholar 

  86. Saab S, Chang AJ, Comulada S, et al. Outcomes of hepatitis C- and hepatitis B core antibody-positive grafts in orthotopic liver transplantation. Liver Transpl. 2003;9:1053–61.

    Article  Google Scholar 

  87. Burr AT, Li Y, Tseng JF, et al. Survival after liver transplantation using hepatitis C virus-positive donor allografts: case-controlled analysis of the UNOS database. World J Surg. 2011;35:1590–5.

    Article  Google Scholar 

  88. Northup PG, Argo CK, Nguyen DT, et al. Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US National Transplant Registry analysis. Transpl Int. 2010;23:1038–44.

    Article  Google Scholar 

  89. Alvaro E, Abradelo M, Fuertes A, et al. Liver transplantation from anti hepatitis C virus-positive donors: our experience. Transplant Proc. 2012;44:1475–8.

    Article  CAS  Google Scholar 

  90. Ballarin R, Cucchetti A, Spaggiari M, et al. Long-term follow-up and outcome of liver transplantation from anti-hepatitis C virus-positive donors: a European multicentric case-control study. Transplantation. 2011;91:1265–72.

    Article  Google Scholar 

  91. Saab S, Ghobrial RM, Ibrahim AB, et al. Hepatitis C positive grafts may be used in orthotopic liver transplantation: a matched analysis. Am J Transplant. 2003;3:1167–72.

    Article  Google Scholar 

  92. Marroquin CE, Marino G, Kuo PC, et al. Transplantation of hepatitis C-positive livers in hepatitis C-positive patients is equivalent to transplanting hepatitis C-negative livers. Liver Transpl. 2001;7:762–8.

    Article  CAS  Google Scholar 

  93. Vargas HE, Laskus T, Wang LF, et al. Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology. 1999;117:149–53.

    Article  CAS  Google Scholar 

  94. Testa G, Goldstein RM, Netto G, et al. Long-term outcome of patients transplanted with livers from hepatitis C-positive donors. Transplantation. 1998;65:925–9.

    Article  CAS  Google Scholar 

  95. Kamar N, Legrand-Abravanel F, Izopet J, et al. Hepatitis E virus: what transplant physicians should know. Am J Transplant. 2012;12:2281–7.

    Article  CAS  Google Scholar 

  96. Dalton HR, Bendall R, Ijaz S, et al. Hepatitis E: an emerging infection in developed countries. Lancet Infect Dis. 2008;8:698–709.

    Article  Google Scholar 

  97. Dalton HR, Bendall RP, Keane FE, et al. Persistent carriage of hepatitis E virus in patients with HIV infection. N Engl J Med. 2009;361:1025–7.

    Article  CAS  Google Scholar 

  98. Ollier L, Tieulie N, Sanderson F, et al. Chronic hepatitis after hepatitis E virus infection in a patient with non-Hodgkin lymphoma taking rituximab. Ann Intern Med. 2009;150:430–1.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Digestive and Liver Diseases, BLK Hospital, Delhi, India

    Manav Wadhawan & Saurabh Argal

Authors
  1. Manav Wadhawan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Saurabh Argal
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Liver Transplant, GI Anesthesia & Intensive Care, Medanta The Medicity, Gurgaon, India

    Vijay Vohra

  2. Liver Transplant, GI Anesthesia & Critical Care, Medanta The Medicity, Gurgaon, Haryana, India

    Nikunj Gupta

  3. Liver Transplant & General Anaesthesia, Narayana Superspeciality Hospital, Gurgaon, India

    Annu Sarin Jolly

  4. Liver Transplant, GI Anesthesia & Critical Care, Formerly at Medanta The Medicity, Gurgaon, India

    Seema Bhalotra

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Wadhawan, M., Argal, S. (2023). Viral Markers and Their Relevance in Liver Disease and Transplantation. In: Vohra, V., Gupta, N., Jolly, A.S., Bhalotra, S. (eds) Peri-operative Anesthetic Management in Liver Transplantation. Springer, Singapore. https://doi.org/10.1007/978-981-19-6045-1_6

Download citation

  • DOI: https://doi.org/10.1007/978-981-19-6045-1_6

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-19-6044-4

  • Online ISBN: 978-981-19-6045-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation